** Abbott Laboratories ABT.N on Wednesday forecast 2025 profit in line with Wall Street estimates as it expects new medical device launches and growing demand for its glucose monitors to offset a hit from weakness in China and a stronger dollar
** Median PT of 28 brokerages covering the stock is $134 - data compiled by LSEG
HEALTHY ON GROWTH AND INNOVATION
** J.P. Morgan ("overweight") is bullish on ABT's organic sales growth outlook for 2025 and demand for glucose monitors
** RBC ("outperform," PT: $135) says ABT is well-positioned and expects continued growth driven by innovations and a strong product pipeline
** TD Cowen ("buy," PT: $135) expects ABT to continue to deliver growth across its various segments, driven by innovation and market expansion
** UBS ("buy," PT: $148) says outlook for organic sales growth appears 'conservative'
** "We believe the sustainability of ABT’s MedTech business growth trajectory remains underappreciated" - UBS
(Reporting by Rashika Singh in Bengaluru)
((rashika.singh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.